5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of February 2018. Valeant was also able to highlight rebounding sales for gastrointestinal-disease drug Xifaxan.
But while Valeant reported some positives, there was plenty in the company's update that continues to be of concern for investors. Here are five things management said in the company's second-quarter conference call that suggest the situation is getting worse for the drugmaker. (Quotes from S&P Global Market Intelligence.)
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Stock
€5.31
1.490%
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Bausch Health Companies Inc..
Based on the current price of 5.31 € the target price of 12 € shows a potential of 125.86% for Bausch Health Companies Inc. which would more than double the current price.
